Details for New Drug Application (NDA): 206938
✉ Email this page to a colleague
NDA 206938 describes CEFIXIME, which is a drug marketed by Alkem Labs Ltd, Aurobindo Pharma Ltd, Belcher, and Chartwell Rx, and is included in six NDAs. It is available from seven suppliers. Additional details are available on the CEFIXIME profile page.
The generic ingredient in CEFIXIME is cefixime. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the cefixime profile page.
The generic ingredient in CEFIXIME is cefixime. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the cefixime profile page.
Suppliers and Packaging for NDA: 206938
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CEFIXIME | cefixime | FOR SUSPENSION;ORAL | 206938 | ANDA | NorthStar RxLLC | 16714-766 | 16714-766-01 | 50 mL in 1 BOTTLE (16714-766-01) |
| CEFIXIME | cefixime | FOR SUSPENSION;ORAL | 206938 | ANDA | NorthStar RxLLC | 16714-767 | 16714-767-01 | 50 mL in 1 BOTTLE (16714-767-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | 100MG/5ML | ||||
| Approval Date: | Feb 6, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | 200MG/5ML | ||||
| Approval Date: | Feb 6, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
